Eur Rev Med Pharmacol Sci 2016; 20 (11): 2194-2200

MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway

Y.-X. Fan, Y.-Z. Dai, X.-L. Wang, Y.-Q. Ren, J.-J. Han, H. Zhang

Clinical Laboratory, the People’s Hospital of Gaomi, Gaomi, Shandong, China. huizhange@outlook.com


OBJECTIVE: We investigated the involvement of miR-18a upregulation in autophagy regulation and paclitaxel (PTX) resistance in triple negative breast cancer (TNBC) cells.

MATERIALS AND METHODS: PTX resistant MDA-MMB-231/PTX cells were generated using an intermittent, stepwise method. MiR-18a expression was assessed using qRT-PCR. The level of autophagy was assessed by Western blot analysis of LC3B expression and observation of LC3-GFP puncta formation under a fluorescence microscope. The effect of miR-18a mediated autophagy on PTX sensitivity was assessed by measuring IC50 and PTX induced cell apoptosis.

RESULTS: MDA-MB-231/PTX cells had both higher miR-18a expression and basal autophagy than MDA-MB-231 cells. Enforced miR-18a overexpression directly led to increased autophagy in MDA-MB-231 cells, the effect of which was similar to that of rapamycin, a mTOR signaling inhibitor. Following Western blot analysis showed that miR-18a overexpression decreased the expression of p-mTOR and p-p70S6. Therefore, we infer that miR-18a increases autophagy level in MDA-MB-231 cells via inhibiting mTOR signaling pathway. Both drug sensitivity assay and flow cytometry analysis confirmed that the effect of miR-18a on increasing IC50 and decreasing PTX induced apoptosis in MDA-MB-231 cells could largely be abrogated by treatment with bafilomycin A1 (Baf. A1).

CONCLUSIONS: MiR-18a upregulation results in enhanced autophagy via inhibiting mTOR signaling pathway in TNBC cells, which is a mechanism contributing to paclitaxel resistance.

Free PDF Download

To cite this article

Y.-X. Fan, Y.-Z. Dai, X.-L. Wang, Y.-Q. Ren, J.-J. Han, H. Zhang
MiR-18a upregulation enhances autophagy in triple negative cancer cells via inhibiting mTOR signaling pathway

Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 11
Pages: 2194-2200